Solid said that the first patients to receive its Duchenne gene therapy all produced high levels of the target protein, an ...

Results show improved functional outcomes for people with Duchenne muscular dystrophy who are ambulatory. Elevidys, which is ...

The company raised $200 million after early findings hinted its therapy could be more potent than others like it, including ...

Sarepta Therapeutics ... It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 ...

An experimental Duchenne muscular dystrophy gene therapy from Solid Biosciences ... suggest SGT-003 could be more potent than Sarepta Therapeutics’ Elevidys, the only approved Duchenne gene ...

Older age, presence of scoliosis, and other factors were associated with lower predicted forced vital capacity in patients with Duchenne muscular dystrophy using non-invasive ventilation.

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

a gene therapy aimed at treating Duchenne muscular dystrophy. Data from the first three participants, gathered 90 days post-treatment, indicated an average microdystrophin expression of 110% along ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth ...

--(BUSINESS WIRE)--Sarepta Therapeutics ... We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 ...

The company is evaluating whether the drug, which targets cardiac complications, might be used treat patients with other ...